Reinforcing adherence to lipid-lowering therapy after an acute coronary syndrome: A pragmatic randomized controlled trial
Data
2021Language
en
Soggetto
Abstract
Background and aims: Achieving the low-density lipoprotein cholesterol (LDL-C) goal following an acute coronary syndrome (ACS) is a milestone often missed due to suboptimal adherence to secondary prevention treatments. Whether improved adherence could result in reduced LDL-C levels is unclear. We aimed to evaluate whether an educational-motivational intervention increases long-term lipid-lowering therapy (LLT) adherence and LDL-C goal attainment rate among post-ACS patients. Methods: IDEAL-LDL was a parallel, two-arm, single-center, pragmatic, investigator-initiated randomized controlled trial. Hospitalized patients for ACS were randomized to a physician-led integrated intervention consisting of an educational session at baseline, followed by regular motivational interviewing phone sessions or usual care. Co-primary outcomes were the LLT adherence (measured by Proportion of Days Covered (PDC); good adherence defined as PDC>80%), and LDL-C goal (<70 mg/dl or 50% reduction from baseline) achievement rate at one year. Results: In total, 360 patients (mean age 62 years, 81% male) were randomized. Overall, good adherence was positively associated with LDL-C goal achievement rate at one year. Median PDC was higher in the intervention group than the control group [0.92 (IQR, 0.82–1.00) vs. 0.86 (0.62–0.98); p = 0.03] while the intervention group had increased odds of good adherence (odds ratio: 1.76 (95% confidence interval 1.02 to 2.62; p = 0.04). However, neither the LDL-C goal achievement rate (49.6% in the intervention vs. 44.9% in the control group; p = 0.49) nor clinical outcomes differed significantly between the two groups. Conclusions: Α multifaceted intervention improved LLT adherence in post-ACS patients without a significant difference in LDL-C goal attainment. © 2021 Elsevier B.V.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Serum triglyceride and cholesterol concentrations and lipoprotein profiles in dogs with naturally occurring pancreatitis and healthy control dogs
Xenoulis P.G., Cammarata P.J., Walzem R.L., Suchodolski J.S., Steiner J.M. (2020)Background: Previous studies have reported an association between hyperlipidemia and pancreatitis in dogs, but details of this association remain poorly defined. Hypothesis/Objectives: To compare serum triglyceride and ... -
Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium
Bahls M., Lorenz M.W., Dörr M., Gao L., Kitagawa K., Tuomainen T.-P., Agewall S., Berenson G., Catapano A.L., Norata G.D., Bots M.L., van Gilst W., Asselbergs F.W., Brouwers F.P., Uthoff H., Sander D., Poppert H., Hecht Olsen M., Empana J.P., Schminke U., Baldassarre D., Veglia F., Franco O.H., Kavousi M., de Groot E., Mathiesen E.B., Grigore L., Polak J.F., Rundek T., Stehouwer C.D.A., Skilton M.R., Hatzitolios A.I., Savopoulos C., Ntaios G., Plichart M., McLachlan S., Lind L., Willeit P., Steinmetz H., Desvarieux M., Ikram M.A., Johnsen S.H., Schmidt C., Willeit J., Ducimetiere P., Price J.F., Bergström G., Kauhanen J., Kiechl S., Sitzer M., Bickel H., Sacco R.L., Hofman A., Völzke H., Thompson S.G., on behalf of the PROG-IMT Study Group (2020)Aims: Averaged measurements, but not the progression based on multiple assessments of carotid intima-media thickness, (cIMT) are predictive of cardiovascular disease (CVD) events in individuals. Whether this is true for ... -
Impact of flavonols on cardiometabolic biomarkers: A meta-analysis of randomized controlled human trials to explore the role of inter-individual variability
Menezes R., Rodriguez-Mateos A., Kaltsatou A., González-Sarrías A., Greyling A., Giannaki C., Andres-Lacueva C., Milenkovic D., Gibney E.R., Dumont J., Schär M., Garcia-Aloy M., Palma-Duran S.A., Ruskovska T., Maksimova V., Combet E., Pinto P. (2017)Several epidemiological studies have linked flavonols with decreased risk of cardiovascular disease (CVD). However, some heterogeneity in the individual physiological responses to the consumption of these compounds has ...